HS-10504
Phase 3Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.HS-10504 is one of 45 small molecule programs targeting Advanced or Metastatic NSCLC. It is currently in Phase 3.
3
Indications
5
Total Trials
5
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Phase IB
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 2
Ibrance
PfizerPhase 2
Verzenio
Eli LillyPhase 2
Afinitor
NovartisPhase 2
Kisqali
NovartisPhase 2
Bavencio
EMD SeronoPhase 2
HS-10504
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3
Lisaftoclax
Ascentage Pharma Group Inc.Phase 2
R-CHOP
IIncyte Biosciences Japan GK
Phase 2
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced or Metastatic NSCLC1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HS-10504. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details